News

Technology News

FDA Approves Biogen Idec ELOCTATE

Monday, June 9, 2014 5:15:00 AM PDT | VentureDeal
   Cambridge, Massachusetts  --  Pharmaceutical company Biogen Idec (NASDAQ: BIIB) said that the US Food and Drug Administration (FDA) has approved its anti-hemophilic Factor Fc Fusion Protein for marketing in the United States.

Called ELOCTATE, the medicine is the first recombinant hemophilia A therapy with prolonged circulation in the body, according to Biogen Idec.

It promises to provide protection from bleeding episodes with prolonged circulation and according to the company marks the first significant hemophilia a treatment advance in more than 20 years.

Hemophilia A is a chronic, rare, genetic disorder where the ability of a person's blood to clot is impaired.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1